Vivesto reports positive Paccal Vet topline in 21-cat study
Vivesto AB said preliminary topline data showed anti-tumor activity and an MTD higher than expected in its 21-cat Paccal Vet dose-finding study. Final analyzed results are expected in Q4 2026.
Vivesto AB said preliminary topline data from a 21-cat Paccal Vet dose-finding study showed anti-tumor activity and a higher-than-expected MTD, supporting continued development. Final analyzed results are expected in Q4 2026.